key: cord-0741208-heh6kwug authors: Masyeni, Sri; Santoso, Marsha S.; Widyaningsih, Putu Dyah; Wedha Asmara, D.G.; Nainu, Firzan; Harapan, Harapan; Tedjo Sasmono, R. title: Serological cross-reaction and co-infection of dengue and COVID-19 in Asia: Experience from Indonesia date: 2020-10-25 journal: Int J Infect Dis DOI: 10.1016/j.ijid.2020.10.043 sha: dd6387d76eb7ec83166e001078d4855b9cc1d4bc doc_id: 741208 cord_uid: heh6kwug Similar symptoms and laboratory findings between dengue and coronavirus disease 2019 (COVID-19) pose a diagnostic challenge in some dengue-endemic countries in Asia. In this study, we reported three cases of suspected COVID-19-dengue co-infection in hospitals of Bali, Indonesia. Serological data demonstrated that patients with positive results on dengue virus (DENV) NS1 antigen and anti-dengue IgM were also reactive to COVID-19 rapid antibody tests, suggesting dengue-COVID-19 co-infection. However, two patients were later confirmed negative for SARS-CoV-2 by qRT-PCR, implying a plausible cross-reactivity of anti-dengue and anti-COVID-19 antibodies in the serological test. Co-infection of dengue and COVID-19 was evident in one patient, following confirmation of SARS-CoV-2 by qRT-PCR and DENV infection using NS1 antigen serology test. This case was the first case of dengue and COVID-19 co-infection in Indonesia and at the same time revealed possible cross-reactivity between SARS-CoV-2 and DENV antibodies based on rapid serological tests. Our study shall raise public health concern for COVID-19 and dengue detection in Indonesia as well as in other dengue-endemic countries as it may present a tip of the dangerous iceberg for the nations’ effort to manage of both pathogens. Coronavirus disease 2019 (COVID-19) is a respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has now spread to most countries around the world, resulting in a global pandemic (Harapan et al., 2020a) . SARS-CoV-2 is primarily transmitted from person-to-person through droplets while coughing and sneezing, from symptomatic, and pre-symptomatic patients and probably from asymptomatic individuals (Bai et al., 2020) . Although there is no specific drugs for COVID-19, multiple drugs are being assessed in clinical trials (Frediansyah et al., 2020) . The pandemic is still ongoing in Asian countries in which dengue, caused by dengue virus (DENV), has been endemic for decades. Some countries in the region are facing dengue outbreak amid the COVID-19 pandemic creating a double-burden on resources and health systems (Harapan et al., 2020b) . In addition, with similar clinical symptoms of both diseases, this creates a critical problem of misdiagnosis and the possibility of double infection occurring within the same individual at the same time. Rapid tests are useful for easy, convenient, and fast diagnosis, particularly in areas where diagnostic capabilities are limited. Numerous rapid tests for the detection of COVID-19 antibodies are commercially available and widely used soon after the COVID-9 pandemic, while dengue antigen/antibody rapid tests have been available for years. However, the accuracy of these tests are varied, and influenced by which day in the disease progression the test is performed (Blacksell et al., 2011 , Deeks et al., 2020 . Confirmatory testing for both COVID-19 and dengue is through nucleic acid amplification tests using polymerase chain reaction (PCR) tests. However oftentimes these require referral to more advanced facilities, adding time to the yield of results. Altogether these create consequences on both patient care and public health in particular, in diagnosing the COVID-19 cases especially in low resources countries in Asia. In this case-series, we outlined and compared three cases of suspected J o u r n a l P r e -p r o o f cross-reactivity of SARS-CoV-2 and DENV based on rapid serology tests in Indonesia. Three cases of suspected COVID-19-dengue co-infection were reported in Kasih Ibu Hospital and Sanjiwani Hospital in Denpasar, Bali, Indonesia. The first case was a 24-year old woman presenting with a 2-day onset of high and continuous fever, as well as myalgia, headache, arthralgia, retro-orbital pain, nausea, and vomiting. She did not report cough, sore throat, or shortness of breath. Other vitals were normal upon admission, and initial blood work showed leucopenia (2,380/μL), thrombocyte count was 124,000/μL, and slightly elevated levels of aspartate aminotransferase (AST, 45 U/L) and alanine transaminase (ALT, 57 U/L However, their daughter regularly leaves home to work and shop for groceries at the market. A follow up test revealed that her husband was tested positive for SARS-CoV-2 while the daughter was, surprisingly, negative. In dengue-endemic regions such as in Asia, misdiagnosis between COVID-19 and dengue can be highly problematic that could affect management of the diseases. This is mainly because approximately 80% of COVID-19 cases have mild to moderate cases with unspecific symptoms and mimicking dengue (Henrina et al., 2020) . Apart from fever, which is the chief complaint of most cases of dengue and COVID-19, skin manifestation including rash or petechiae commonly found in dengue, has also commonly been reported in COVID-19 (Criado et al., 2020) ; hence increasing the challenge to discriminate one from another. One of the easiest, the most convenient, and the fastest point-of-care testing to diagnose dengue and COVID-19 is by rapid serology tests. However, cross-reactivity between COVID-19 and dengue has been reported in Singapore (Yan et al., 2020), Thailand (Prasitsirikul et al., 2020) , and Indonesia (Kembuan, 2020) where dengue antibodies were detected in confirmed COVID-19 patients (i.e. false-positive dengue serology among COVID-19 patients). Our data also suggested the possible cross-reactivity between DENV and SARS-CoV-2 which lead to false-positive COVID-19 serology among dengue patients. This also have been reported previously in Italy where 1 out of 44 DENV-positive sera resulted false-positive result for COVID-19 antibodies (Spinicci et al., 2020) . Our study also emphasizes the possibility of co-infection of DENV and SARS-CoV-2 in dengue-endemic countries in Asia that might require special management strategies in clinical settings. A recent study found that, a false-positive result could occur for both false-positive COVID-19 serology among dengue patients and reciprocally, dengue serology among COVID-19 patients (Lustig et al., 2020) . The cross-reactivity between SARS-CoV-2 and DENVs using rapid serology test will be a significant hurdle to rely on the laboratory diagnosis of COVID-19 (as well as dengue) based on the use of rapid serology tests, particularly at the early phase of Mayotte of French (Epelboin et al., 2020) . Nevertheless possible co-infection also have been noticed in Asia (Miah and Husna, 2020) . A study in Bangladesh found that co-infection occurred among 25% out of 20 patients and co-infection was associated with high mortality rate (Saddique et al., 2020) alarming the dengue-endemic countries in the region. Therefore, maintaining dengue preventive measures including enhancing vector control measurers amid COVID-19 pandemic is urgently needed. In addition, establishing more laboratory testing facilities that are able to run the PCR testing is critical. Our study provided the evidence of cross-reactivity between DENV and SARS-CoV-2 which lead to false-positive COVID-19 serology among dengue patients. This underscores the importance of a simple and affordable rapid test that is capable of differentiating DENV and SARS-CoV-2 with high sensitivity at the early phase of infection as well as enhancing the laboratory network capacities in the region. In addition, healthcare workers in dengue-endemic countries across the Asian continent should be aware of co-infection of DENV and SARS-CoV-2 and its dangerous impact on the patients' mortality rate. By refining the existing guidelines to accommodate the differentiation of both infectious diseases (and their J o u r n a l P r e -p r o o f Presumed Asymptomatic Carrier Transmission of COVID-19 Evaluation of six commercial point-of-care tests for diagnosis of acute dengue infections: the need for combining NS1 antigen and IgM/IgG antibody detection to achieve acceptable levels of accuracy Lessons from dermatology about inflammatory responses in Covid-19 Antibody tests for identification of current and past infection with SARS-CoV-2 COVID-19 and dengue co-infection in a returning traveller Antivirals for COVID-19: A critical review Coronavirus disease 2019 (COVID-19): A literature review COVID-19 and dengue: Double punches for dengue-endemic countries in Asia Coronavirus Disease of 2019: a Mimicker of Dengue Infection? Dengue serology in Indonesian COVID-19 patients: Coinfection or serological overlap? Potential antigenic cross-reactivity between SARS-CoV-2 and Dengue viruses Coinfection, coepidemics of COVID-19, and dengue in dengue-endemic countries: A serious health concern Nurse infected with Covid-19 from a provisional dengue patient Emergence of coinfection of COVID-19 and dengue: A serious public health threat Low risk of serological cross-reactivity between dengue and COVID-19 Co-infection of dengue and COVID-19: A case report We would like to thank patients and medical staff involved in this study.